News

AlphaDetail Inc. Names Anthony Quagliata to Position of Director, Sales & Marketing
AlphaDetail, Healthcare Market Research Specialist, Named to the Honomichl Top 50
AlphaDetail AlphaPulseTM: Anticipated Impact of CATT Trial in Wet AMD Treatment
AlphaDetail Commemorates 10-Year Anniversary by Community Volunteering
AlphaDetail Revenue Soars 30% in 2010
Turning the Tables on Measuring Client Satisfaction
AlphaDetail Launches RapidRecruit: A New Healthcare Market Research Field and Tab Service
AlphaDetail Names Rishi Varma to Serve as President and CEO
Tracking Studies: The Advantage of Integration and Speed
Physicians Anticipate Higher Prescribing Based on JUPITER Study
AlphaDetail, Inc. Continues Bi-coastal Expansion
Most Practicing Physicians React Positively to FDA Panel’s Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
ASCO Results: Oncologists Rank Genentech Number One
AlphaDetail, Inc. Announces Launch of New Web-Based KOL Online Reporter (KOLORTM)
AlphaDetail, Inc. Expands Management Team
AlphaDetail, Inc. Expands Qualitative Research Capabilities
AlphaDetail, Inc. Affirms Commitment to Local East Coast Presence

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail Inc. Names Anthony Quagliata to Position of Director, Sales & Marketing

San Mateo, California –October 13, 2011

AlphaDetail Inc., a leader in global healthcare market research and influence network mapping, has named Anthony Quagliata to the role of Director, Sales and Marketing.

Mr. Quagliata, who previously held the position of Vice President, Client Development at Harris Interactive, will be responsible for organization-wide sales and marketing efforts as well as supporting new product development at AlphaDetail. "I am truly excited to join AlphaDetail, a company with one of the strongest reputations in healthcare market research, a large and active panel of healthcare professionals, and cutting-edge technology solutions”, said Mr. Quagliata.

In his new role, Mr. Quagliata brings over 11 years of healthcare industry experience from various sales, consulting, and market research roles.

Rishi Varma, AlphaDetail’s CEO, said, “We are excited that Anthony has joined our team to bolster AlphaDetail’s exceptional growth in the US and global market research industry.  We look forward to working with Anthony to continue to deliver the highest quality research for our clients”.

Mr. Quagliata holds an MBA from New York University's Stern School of Business, and a BA in Molecular Biology and Philosophy & Religion from Colgate University.

About AlphaDetail, Inc.:

AlphaDetail is a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that include a team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our clients’ most challenging questions. Client satisfaction and execution excellence are core to AlphaDetail’s mission, demonstrated by client satisfaction scores that are among the highest in the industry.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Healthcare Market Research Specialist, Named to the Honomichl Top 50

San Mateo, California – June 20, 2011

AlphaDetail Inc., a leader in global healthcare primary market research and influence network mapping, has been named as one of the top 50 market research firms in the United States.

Rishi Varma, AlphaDetail’s CEO, said “it is a great honor to be part of the Honomichl 50, and a testament to our company’s unique blend of high-touch client service, in-house panel of physicians and allied health professionals, and innovative technology.  Our performance makes us one of the fastest growing companies on the Honomichl 50 and the only company on the list focused solely on custom primary research for the pharmaceutical, biotech, and medical device industries”.

The company’s record performance included major advances across a broad array of clients and product lines.  Major contributors to revenue growth include:

  • Global studies increased 120% with strong growth from Emerging Markets
  • Early stage product profile testing and market modeling increased 114% supported by advances in discrete choice techniques

  • ATU / Tracking solutions increased 44% bolstered by portfolio-wide solutions supported by the AlphaMonitorTM web-based portal

  • KOL mapping increased 17% fueled by key new product enhancements that more closely integrate multiple sources of information into a holistic understanding of influence

  • Revenues from the 5 largest clients grew 48% while the company simultaneously broadened its overall client base

Rishi Varma continued, “We celebrate this achievement with client satisfaction scores among the highest in the industry, continued strong growth, an expanding portfolio of offerings, and a world-class team.  We welcome pharmaceutical and biotech clients who have not experienced AlphaDetail to reach out to us to learn more”.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients.  We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that includes a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail AlphaPulseTM: Anticipated Impact of CATT Trial in Wet AMD Treatment

San Mateo, California – May 16, 2011

On April 28, 2011 the New England Journal of Medicine released highly anticipated one-year results of the ongoing “Comparisons of Age-Related Macular Degeneration Treatments Trials” (CATT).

AlphaDetail Inc., a leader in global ophthalmology primary market research and influence network mapping, has its latest AlphaPulseTM survey with 120 Ophthalmologists to gauge their reactions on the heels of this important news.

Amy Tsang, a Director at AlphaDetail, explained “the use of Avastin vs. Lucentis in Wet AMD has been debated among eye care professionals for years, and many anticipated that these results could bring closure to the issue”.

While results from the trial confirmed that Avastin is non-inferior to Lucentis on visual acuity efficacy measures, the results related to level of risk associated with serious adverse events are less definitive.

  • 68% of surveyed Ophthalmologists are currently aware of the CATT trial results.
  • Perceived Benefits of Avastin
    • Over three-quarters of Ophthalmologists agree that the results from the CATT trial provide evidence that Avastin’s cost savings outweigh its potential risks in Wet AMD.  

    • Avastin is currently the dominant anti-VEGF therapy used to treat Wet AMD in the United States and this dominance is expected to continue among newly diagnosed patients in the future.

    • Based on the CATT trial results, Ophthalmologists intend to switch 10-15% of their Wet AMD patients currently on Lucentis to Avastin over the next 6 months.
  • Perceived Benefits of Lucentis

    • Two-thirds of Ophthalmologists agree that Lucentis’ superiority over Avastin in other efficacy-related attributes, such as lowering retinal thickness and decreasing retinal fluid, are important considerations when selecting the appropriate therapy for their patients.
    • Similarly, two-thirds of Ophthalmologists agree that data supporting equivalent long term efficacy between Lucentis and Avastin is still needed.
    • Finally, Ophthalmologists are divided on their level of concern about mortality rates and risk of hemorrhagic stroke with Avastin compared to Lucentis as shown in an analysis of 77,886 Wet AMD patients on Medicare.

 

To learn more about this study and to receive full results, please contact Amy Tsang at Amy.Tsang@alphadetail.com or (650) 581-3127.

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail Commemorates 10-Year Anniversary by Community Volunteering

San Mateo, California – March 28, 2011

AlphaDetail, a leader in global primary market research for the pharmaceutical and biotech industries, just completed a year of record revenue and profitability, making it one of the fastest growing market research companies in the United States.
 
“On March 21, 2011 – the first day of spring – AlphaDetail celebrated its 10 year anniversary”, announced Rishi Varma, President & CEO.

The company has a long history of philanthropy, supporting a wide range of causes over the years.  These include helping victims of devastating natural disasters far from home (e.g. Southeast Asia Tsunami, Hurricane Katrina, Haiti Earthquake, Japan Earthquake and Tsunami) as well as supporting and helping the company’s local communities (e.g. SF AIDS Walk, Habitat for Humanity, Save the Bay).

AlphaDetail employees volunteered at three organizations on March 21: two in the San Francisco Bay Area, and one in the Horsham, PA area.

  • MedShare in San Leandro, CA is an organization that distributes medical supplies to communities in need around the world.  Their shipments of medical supplies and equipment have brought healing and the promise of better lives to 85 countries and countless patients.
  • Manna on Main Street in Landsale, PA was founded in 1981 and has grown to be a place where those seeking help and those willing to help have gathered to work together. Manna provides a soup kitchen and food cupboard, and a variety of other programs to help individuals in need. The vision of Manna on Main Street is "that everyone might be fed."
  • The SF Food Bank, in San Francisco, CA collects millions of pounds of food from growers, packers, processors, manufacturers, the USDA and grocery stores.  Volunteers sort, repack and shelve over 350 tons of food at our warehouse every week.  In all, the SF Food Bank serves over 147,000 people each year.

 

Rishi Varma explained, “I personally can’t think of a more appropriate way to commemorate our 10-year anniversary than by helping those who are less fortunate than us”.
 

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients.  We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that includes a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail Revenue Soars 30% in 2010

San Mateo, California - February 10, 2011 / PRNewswire

AlphaDetail, a leader in global primary market research for the pharmaceutical and biotech industries, reported a 30% increase in revenue in 2010, exceeding $18.5M in annual revenue for the first time in the company’s history.

“Our clients have delivered a loud and clear message that AlphaDetail provides the marketing research solutions that get at the heart of their strategic information needs” says Rishi Varma, CEO and President of AlphaDetail. “Our performance in 2010 makes us one of the fastest growing market research companies in the United States”.

The company’s record performance included major advances across a broad array of clients and product lines.  Major contributors to revenue growth include:

  • Global studies increased 120% with strong growth from Emerging Markets
  • Early stage product profile testing and market modeling increased 114% supported by advances in discrete choice techniques
  • ATU / Tracking solutions increased 44% bolstered by portfolio-wide solutions supported by the AlphaMonitorTM web-based portal
  • KOL mapping increased 17% fueled by key new product enhancements that more closely integrate multiple sources of information into a holistic understanding of influence
  • Revenues from the 5 largest clients grew 48% while the company simultaneously broadened its overall client base.

Rishi Varma continued, “We approach AlphaDetail’s 10 year anniversary with strong growth, an expanding portfolio of offerings, a world-class team, and the highest client satisfaction scores in the industry”.
 

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients.  We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community.  AlphaDetail is built on one of the industry’s strongest foundations that includes a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

FOR IMMEDIATE RELEASE

Turning the Tables on Measuring Client Satisfaction

San Mateo, California - April 7, 2010 / PRNewswire

With nearly a decade’s experience assisting our clients effectively launch and commercialize new prescription therapies, vaccines and medical devices, AlphaDetail, a global leader in primary marketing research, decided to turn the tables and do a quantitative analysis of something new: its own customer satisfaction.

“We work closely with our clients to design studies that provide insights to help our clients optimize their brand performance” says Rishi Varma, CEO and President of AlphaDetail. “Starting in 2009, we decided to put our money where our mouth is by measuring the success of our own performance”.

The cumulative % Top 2 Box results as of the end of June, 2010 are provided below.

Overall satisfaction with AlphaDetail – 98%
Likelihood to recommend AlphaDetail – 98%
Study design / methodology recommendations – 98%
Questionnaire / discussion guide design – 93%
Respondent recruiting – 94%
Timeliness of deliverables – 98%
Client service – 98%
Insightfulness of final presentation – 92%
Therapeutic area knowledge – 94%

View the survey results and client quotes

Rishi Varma went on to say “From the day we opened our doors for business in 2001, we have been driven by an unbending commitment to excellence.  The entire AlphaDetail team is delighted by our client satisfaction survey results and the validation that we are indeed achieving our vision”.
 

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail Launches RapidRecruit: A New Healthcare Market Research Field and Tab Service

San Mateo, California - July 22, 2010 / PRNewswire

AlphaDetail, an innovator in pharmaceutical marketing research, is proud to launch RapidRecruit, an expansion of its healthcare field and tab services for market research organizations, ad agencies, and consulting firms that need a fieldwork partner.

AlphaDetail has built and maintains a large US network of physicians and healthcare providers.  This network of active participants allows AlphaDetail and our customers to field large studies quickly and cost effectively. 

AlphaDetail’s in-house programming and quality assurance staff has extensive experience developing complex surveys for the healthcare market utilizing the Confirmit software platform and the latest in conjoint survey design using Sawtooth Software.  Clients also have access real-time data reporting through the AlphaMonitor™ reporting portal.

Roger Jensen, Vice President of Operations at AlphaDetail, said that “AlphaDetail RapidRecruit is an exciting opportunity for us to offer the broad coverage of our active network, programming, and fielding expertise to customers who need rapid, cost-effective fielding of market research studies”. 

To learn more about AlphaDetail RapidRecruit, please contact Roger Jensen, Vice President of Operations at Roger.Jensen@rapidrecuit.com or (650) 581-3146 or visit us at http://www.rapidrecruit.com.
 

About AlphaDetail RapidRecruit:

AlphaDetail RapidRecruit is an independent fielding organization within AlphaDetail, Inc.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as market research, advertising, and consulting organizations.

Contact Information:

Roger Jensen, Vice President of Operations
(650) 581-3146
Roger.Jensen@rapidrecuit.com

Back to Top

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail Names Rishi Varma to Serve as President and CEO

San Mateo, California - January 18, 2010 / PRNewswire

AlphaDetail, an innovator in pharmaceutical marketing research, is pleased to announce that Rishi Varma has been appointed President and CEO by the Board of Directors, effective January 1, 2010.

Mr. Varma co-founded AlphaDetail almost nine years ago and has held senior level positions at AlphaDetail, overseeing each major functional area of the business.  In addition, he has worked closely with pharmaceutical and biotech clients on designing and implementing hundreds of marketing research studies.  This experience, combined with his 14+ years working in the pharmaceutical and biotech industries, serves Mr. Varma well as he assumes the duties of the CEO.

Carl Spetzler, an AlphaDetail board member, said "Rishi was the natural choice for President & CEO given his history with the company and deep understanding of our core business. We are impressed by Rishi’s emphasis on hiring and developing the highest quality market research professionals, his insight into the forces that will shape our industry in the future and the level of mutual respect he shares with his clients, employees, and partners."

Mr. Varma said, “I am excited to take on this expanded role at AlphaDetail.  We have just completed our most successful year in the company’s history, and I look forward to building on our successes by continuing to focus on high research quality, an unparalleled commitment to client service, a strong and growing panel of respondents, and cutting-edge technology.”

Prior to AlphaDetail, as a senior engagement manager for Strategic Decisions Group (SDG), Rishi helped top tier pharmaceutical companies in strategic development and process design throughout the R&D and marketing value chain.  He also led the development of the SDG biotech practice.

Rishi holds a B.S. in industrial engineering and a M.S. in decision analysis from Stanford University.

To learn more about AlphaDetail, please contact Rishi Varma at rishi.varma@alphadetail.com or (650) 581-3116. , or visit us at http://www.alphadetail.com/corp/Home.do

 
About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

FOR IMMEDIATE RELEASE

Tracking Studies: The Advantage of Integration and Speed

San Mateo, California - October 20, 2009

AlphaDetail, an innovator in pharmaceutical marketing research, is pleased to introduce two new features to its suite of tracking services: AlphaLink and AlphaMonitor.

AlphaLink helps clients better understand their competitive landscape by integrating secondary research with tracking study results. “One of the biggest issues facing clients today is managing through vast amounts of data, gathered from a number of different sources,” says Rishi Varma, co-founder of AlphaDetail. “AlphaLink provides an integrated view of a market, enabling a more focused, holistic market understanding.”

AlphaMonitor provides real-time online access with up-to-the-minute results for any of the company’s tracking services – from continuous tracking to monitoring key variables in periodic tracking studies. “Pharmaceutical and biotech marketers are frequently looking for fast insights to react to market changes” reports Dave Johnson, Vice President of AlphaDetail’s Professional Services team. “AlphaMonitor offers instant views and dynamic access to study results that enable marketers to quickly understand and react to feedback from the market.” 

To learn more about AlphaDetail’s Tracking services, please contact Rishi Varma at rishi.varma@alphadetail.com or (650) 581-3116. , or visit us at http://www.alphadetail.com/corp/Home.do

 
About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

FOR IMMEDIATE RELEASE

Physicians Anticipate Higher Prescribing Based on JUPITER Study

San Mateo, California - November 21, 2008

Just three days after the JUPITER trial results were presented at the American Heart Association meeting and simultaneously published online by the New England Journal of Medicine, an AlphaDetail survey of more than 100 primary care physicians shows that physicians anticipate a 14% increase in the use of drug therapy among their hypercholesterolemia patients, particularly for low to moderate risk patients.

The JUPITER study showed that CRESTOR (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events by 44% compared with placebo among men and women with elevated high-sensitivity C-reactive protein (hs-CRP) but low to normal low density lipoprotein cholesterol (LDL-C).

News about JUPITER spread quickly: Two-thirds of the physicians surveyed were already aware of the study results within days of its release. Nearly 90% of the physicians surveyed report that they found the study results to be positive, emphasizing how compelling they found the findings. However, some physicians feel more data is needed and question if this benefit applies to all statins or is specific to CRESTOR.

Physicians report that they recognize the value of C-reactive protein. Two-fifths of physicians indicate that they strongly or very strongly agree that hs-CRP plays an important role in cardiovascular disease. The most intriguing part of the 2008 study lies in physicians future expectations. Following the JUPITER study results, physicians report that they anticipate more than doubling the percent of patients for whom they test hs-CRP. The increased testing is likely to drive future prescribing behavior, particularly for patients with low to moderate risk factors.

Please contact Rishi Varma at AlphaDetail for more information on the AlphaPulse study results or for additional insight regarding the market impact of the JUPITER study.

 
About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Inc. Continues Bi-coastal Expansion

San Mateo, California - November 4, 2008

AlphaDetail Inc. is growing.  As a leader in primary market research and influence network mapping solutions to the Global Life Sciences Industry, the company is pleased to announce the addition of 3 new senior staff members to its Professional Services Group.   

Gloria Lee is a Director of Professional Services, based in Alphadetail’s San Mateo, California headquarters office.  Gloria comes to AlphaDetail from Yahoo! where she had been the Director of Monetization.  Prior to Yahoo!, Gloria spent seven years and Duff & Phelps, most recently as Director of Market & Financial Analytics Healthcare Practice.  Gloria has also held positions as a Consultant at ZS Associates and as a Senior Manager of Strategic Planning and Development at Pfizer.  She holds an S.M. in Operations Research from M.I.T., as well as an M.A. and B.A. in Mathematics from the University of Cambridge.

Jim Daly is a Senior Director of Business Development, based in AlphaDetail’s Horsham, Pennsylvania office.  Jim has more than 18 years of pharmaceutical consulting and business experience.  Prior to joining AlphaDetail, Jim worked at Innovex where he supported clients with Contract Sales Force Deployment services, including Physician Targeting & Alignment solutions.  Jim also held senior positions at IMS Health and Health Products Research, where he developed business solutions in the areas of Portfolio Optimization & Resource Allocation, Strategic Product Planning, Marketing Research & Quantitative Analysis.  Jim earned his BS degree in Business Management from Montclair State University.

John Unipan is a Director of Professional Services, also based in the Horsham, Pennsylvania office.  John has over 15 years of healthcare and pharmaceutical experience.  John has supervised and led hundreds of market research studies for leading pharmaceutical, biotech and medical device manufacturers.  Previously John worked for Psyma Incorporated, TagetRx and GfK.  John is an expert in designing and conducting quantitative analysis, and has also personally conducted hundreds of interviews and focus groups with physicians, patients and other healthcare professionals.  John received his Bachelor of Arts degree from Bowdoin College and studied Applied Social Psychology at the graduate level at the Claremont Graduate University.

 
About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail AlphaPulseTM: Most Practicing Physicians React Positively to FDA Panel’s Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.

San Mateo, California - July 7, 2008

After meeting on July 1st and 2nd an FDA advisory panel recommended that all new diabetes drugs should undergo trials to rule out cardiovascular risk.  85% of US cardiologists and 65% of US endocrinologists agree with this recommendation, according to AlphaDetail Inc., a leader in cardiovascular and metabolic primary market research and key opinion leader mapping solutions to the Global Life Sciences Industry.

On July 3rd AlphaDetail launched its latest AlphaPulseTM survey to measure immediate physician awareness and reactions to the panel recommendation.  In a brief on-line survey of 52 cardiologists and 51 endocrinologists AlphaDetail found:

  • Unaided, about 40% of physicians mentioned CV risk associated with diabetes medications as the most important development in diabetes treatment from the past month.
  • When prompted, half of physicians indicated they had heard about the FDA panel recommendation to require cardiovascular safety trials for new diabetes medications - only a day after the news was announced.
  • Although most physicians from both specialties support the recommendation, twice as many cardiologists (33%) vs. endocrinologists (16%) agree strongly with it.
    • However, 22% of endocrinologists disagree with the recommendation primarily because they believe it would stifle innovation and delay the availability of important new therapies.
  • Physicians disagree on the most appropriate implementation of the FDA panel recommendation - two CV safety trials vs. only one trial.
    • However, more physicians believe that the two trial implementation is the most appropriate.
  • Even so, a segment of physicians (25% of cardiologists and 37% of endocrinologists) would support prescribing a new diabetes therapy that is highly efficacious but has CV risk to patients that have no CV risk factors other than diabetes.
    • Physicians have to make a trade-off between controlling diabetes and preventing other diabetes complications vs. preventing CV risk.

 

To learn more about this study, please contact Rishi Varma at rishi.varma@alphadetail.com or (650) 581-3116.

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

ASCO Results: Oncologists Rank Genentech Number One

San Mateo, California - June 9, 2008

When asked which company stood out at last week’s ASCO conference in Chicago, oncologists cited Genentech at the top of the list, according to AlphaDetail Inc., a leader in oncology primary market research and influence network mapping solutions to the Global Life Sciences Industry.

In a brief on-line survey of 103 oncologists conducted soon after the close of the conference, AlphaDetail was able to gather some interesting feedback about oncologist perceptions of the meeting.  The ASCO Annual Meeting attracts more than 30,000 attendees and is considered the premier educational and scientific event in the oncology community.

  • 60% of US oncologists attended the ASCO Annual Meeting.
  • Oncologists rate Genentech #1 on overall image in oncology and cite it as the top company that stood out above the others at ASCO.
  • Oncologists cite the following as the three most important pieces of data presented at ASCO:
    • KRAS status predicts response to first-line cetuximab for metastatic colorectal cancer.
    • Erbitux (cetuximab) + platinum-based chemotherapy extends overall survival in NSCLC vs. chemotherapy alone.
    • Zometa (zoledronic acid) increases survival for premenopausal patients who received adjuvant endocrine therapy for early breast cancer.

To learn more about this study, please contact Rishi Varma at rishi.varma@alphadetail.com or (650) 581-3116.

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Inc. Announces Launch of New Web-Based KOL Online Reporter (KOLORTM)

San Mateo, California - April 18, 2008

Key Opinion Leader reporting never looked easier. AlphaDetail Inc., a leader in primary market research and influence network mapping solutions to the global Life Sciences industry, is proud to announce KOLORTM, a web-based Key Opinion Leader report system that dramatically enhances product deliverables.

KOLORTM brings a variety of benefits to AlphaDetail’s KOL identification process including:

  • Faster results
  • Customizable data presentation configurations
  • Advanced and user friendly search filters.

KOLORTM supports AlphaDetail’s unique KOL identification process, including the integration of primary and secondary research, as well as in-depth KOL profiles. Users are able to configure virtually every aspect of data presentation instantly – column display names, order, and format to name a few.  Clients benefit from secure, 24-hour access and multiple users are able to generate, share, and export custom reports simultaneously.

Additionally, the new web-based tool paves the way for future advances, including the ability to plot nominated and surveyed physicians on Google Maps and an integrated social-network mapping tool to generate network charts. AlphaDetail is pleased to introduce KOLORTM, a unique and powerful KOL reporting tool, as an excellent compliment to the company’s  rigorous and comprehensive KOL product offerings.

To learn more about AlphaDetail’s KOL mapping solution please visit http://www.alphadetail.com/KOL

 
About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Inc. Expands Management Team

San Mateo, California - February, 28

AlphaDetail Inc., a leader in primary market research and influence network mapping solutions to the Global Life Sciences Industry, is proud to announce the addition of Dave Johnson to its management team. Dave joined AlphaDetail in January and serves as the Vice President of Professional Services in the company's Horsham, PA office.

Dave brings AlphaDetail a wide variety of industry-pertinent analytical skills and management experience that will impact the company immediately. During his 15 years of experience in the pharmaceutical industry, he spent the last nine years working for Verispan, most recently as Vice President of the company's 100-person Client Solutions team. In this role, Dave was responsible for managing the company's consulting and marketing research services, supporting virtually all of the industry's leading pharmaceutical and biotech organizations. Prior to Verispan, Dave worked on the marketing research team at Warner-Lambert, supporting the cardiovascular and women's health teams. Dave's other variegated marketing and marketing research experience includes roles at Scott-Levin, Arbitron ratings, IMS Health (London office) and Life Fitness (Munich office).

AlphaDetail CEO Roger Jensen explains, "Dave's background and depth of experience will bring immediate benefits to AlphaDetail. Dave's demonstrated leadership in pharmaceutical market research makes him the ideal person to help us continue our growth and maintain the commitment to quality that our customers expect from AlphaDetail."

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Inc. Expands Qualitative Research Capabilities

San Mateo, California - January, 16

AlphaDetail Inc., a leader in primary market research and influence network mapping solutions to the Global Life Sciences Industry, continues to affirm its commitment to growth and client service by expanding its Qualitative Research Capabilities.

Beth Thompson joined AlphaDetail in December as Director of the qualitative research department. Beth has over 14 years healthcare marketing research and consulting experience, during her tenure at GfK Strategic Marketing, Britnall & Nicolini and as President of her own qualitative consultancy. She is an expert in the area of qualitative research with extensive experience moderating telephone interviews, in-person interviews, dyads/triads, and focus groups.

Beth's experience ranges from pre-launch to post-launch studies and includes exploratory market assessments, pre-positioning/positioning work, concept testing, message development, stimulus testing (detail aids, journal ads, etc.), and war-gaming. She has also conducted qualitative projects in support of quantitative research, such as attribute testing or segmentation analysis. In addition to domestic US-only work, Beth has quite a bit of experience managing large multinational projects as well.

Beth has worked with many of the leading companies in the pharmaceutical industry including Abbott, AstraZeneca, BMS, Eli Lilly, J&J, Pfizer, Novartis, and others. Her work has spanned a broad spectrum of therapeutic areas such as cardiovascular disease, depression/anxiety, diabetes, dyslipidemia, HIV/AIDs, and oncology, to name a few.

Beth has a Ph. D (ABD) in Political Science from Rutger's University and a B.A. in International Relations from the University of Michigan's Honors College.

AlphaDetail CEO Roger Jensen explains, "The addition of an experienced qualitative research professional like Beth is another example of AlphaDetail's commitment to providing an expanding array of services and methodologies to our customers."

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

AlphaDetail, Inc. Affirms Commitment to Local East Coast Presence

San Mateo, California - October 5, 2007

AlphaDetail Inc., a leader in primary market research and influence network mapping solutions to the Global Life Sciences Industry, continues to affirm its commitment to growth and client service by expanding to a new office on the east coast. 

AlphaDetail, Inc. will open a full service office in Horsham, Pennsylvania on November 1, 2007.  This will benefit a large number of clients located in the Eastern Time Zone by providing more opportunities for in-person project interactions and more frequent client visits while simultaneously bolstering project production capacity. 

AlphaDetail, Inc. CEO Roger Jensen explains, "We are extremely excited about our new East Coast office.  It is an important part of our strategic plan to establish a presence here to ensure we deliver the best possible service to our many East Coast customers.  A local presence will also allow us to attract the area's best professionals in healthcare market research."

To complement this exciting news three talented Directors have joined AlphaDetail, and will all be based in the new east coast office: 

Eileen Henne has over 25 years of healthcare and pharmaceutical experience at a number of pharmaceutical companies such as DuPont Merck, Wyeth-Ayerst and Bristol-Myers Squibb. She has also held positions of increasing responsibility at IMS Health and Health Products Research. Eileen received her Bachelor of Science Degree from Neumann College. 

Mike Nestler has over 20 years of marketing research and consulting experience.  Before joining AlphaDetail, Mike has done a significant amount of consulting and project work for Novartis, Bayer, GSK, Merck, Johnson & Johnson and many others. Mike has a BA in Experimental Psychology from McMaster University in Hamilton, Ontario and an MBA from York University in Toronto. 

John Freeman has over 10 years of experience in pharmaceutical marketing research and consulting for Datamonitor, Instinet, Gerson Lehrman Group and GfK Market Measures. John has a BA in Biology from the University of Pennsylvania and a Master of Philosophy in Pharmacology from the University of Cambridge, UK.

Eileen, Mike, and John all build a strong foundation for growth in AlphaDetail's east coast operation and will guide a diverse and powerful new team that reflects AlphaDetail's ongoing commitment to excellent services and delivering an outstanding product.

About AlphaDetail, Inc.:

AlphaDetail, Inc. is an innovator in primary market research and KOL Identification serving the global biopharmaceutical industry.  AlphaDetail’s expertise spans every continent, a wide array of therapeutic areas and every stage of the product life cycle.  Our clients include the top pharmaceutical, biotech and medical device companies in the world, as well as companies of all sizes.  AlphaDetail is built on one of the industry’s strongest foundations that include a large team of exceptional analytical specialists, the industry’s leading technology platform and a flexible approach to research that helps us to answer our client’s most challenging questions.

Contact Information:

Clients
Rishi Varma - President & Chief Executive Officer
(650) 581-3116
rishi.varma@alphadetail.com

Back to Top

AlphaDetail is a member and abides by the rules and regulations of the following professional organizations.
  • Sitemap
  • Terms of Service
  • Privacy Policy